Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

doi:10.4240/wjgs.v14.i5.383

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4255)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

350

WORD

125

HTML

2533

Figures (1-3)

295

Tables (1-1)

172

Sum=3475

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

284

Download

496

Sum=780

May 27, 2022 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Surg. May 27, 2022; 14(5): 383-396
Published online May 27, 2022. doi: 10.4240/wjgs.v14.i5.383

Open in New Tab Full Size Figure Download Figure

Figure 1 Incidence in gastroenteropancreatic organs.

Open in New Tab Full Size Figure Download Figure

Figure 2 Milestones in the diagnosis of neuroendocrine neoplasms[94-106]. ENETS: European Neuroendocrine Tumor Society; ESMO: European Society for Medical Oncology; GEP-NEN: Gastroenteropancreatic neuroendocrine neoplasm; IHC: Immunohistochemistry; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; NEN: Neuroendocrine neoplasm; TNM: Tumor, Node, Metastasis; WHO: World Health Organization.

Open in New Tab Full Size Figure Download Figure

Figure 3 Milestones in the treatment of neuroendocrine neoplasms[107-114]. US FDA: United States Food and Drug Administration; NEN: Neuroendocrine neoplasm; LAR: Long-acting repeatable; PRRT: Peptide receptor radionuclide therapy.

Citation: Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396
URL: https://www.wjgnet.com/1948-9366/full/v14/i5/383.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i5.383